Quick Answer
Kymera Therapeutics, Inc. reported Total Revenue of $39.21 million for the year ending 2025.
- Kymera Therapeutics, Inc. showed a decrease of -16.7% in Total Revenue from 2024 to 2025.
- This data is from Kymera Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2019: $950.0 thousand | Q1 2020: $3.43 million | Q2 2020: $3.29 million | Q3 2020: $14.53 million | Q1 2021: $18.70 million | Q2 2021: $18.52 million | Q3 2021: $20.34 million | Q1 2022: $9.62 million | Q2 2022: $11.51 million | Q3 2022: $9.55 million | Q1 2023: $9.47 million | Q2 2023: $16.51 million | Q3 2023: $4.73 million | Q1 2024: $10.29 million | Q2 2024: $25.65 million | Q3 2024: $3.74 million | Q1 2025: $22.10 million | Q2 2025: $11.48 million | Q3 2025: $2.76 million.
- Over the full 7 years of available data (2019 to 2025), Kymera Therapeutics, Inc.'s Total Revenue has grown by 1,236.4%.
- Historical annual values: Fiscal year 2025: $39.21 million | Fiscal year 2024: $47.07 million | Fiscal year 2023: $78.59 million | Fiscal year 2022: $46.83 million | Fiscal year 2021: $72.83 million | Fiscal year 2020: $34.03 million | Fiscal year 2019: $2.93 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: